New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2014
10:01 EDTTMO, OMED, VSTM, HLT, MTD, SNAK, T, AHPOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AT&T (T) initiated with a Buy at Drexel Hamilton... Ashford Hospitality Prime (AHP) initiated with a Buy at SunTrust... Cypress Energy (CELP) initiated with an Outperform at Raymond James... Hilton Worldwide (HLT) initiated with a Positive at Susquehanna... OncoMed (OMED) initiated with a Buy at Mizuho... RSP Permian (RSPP) initiated with an Overweight at Barclays... The Inventure Group (SNAK) initiated with an Outperform at Wedbush... Verastem (VSTM) initiated with a Buy at Mizuho... Xilinx (XLNX) initiated with a Buy at MKM Partners... RSP Permian (RSPP) initiated with an Outperform at Raymond James... Thermo Fisher (TMO) resumed with an Overweight at JPMorgan... Mettler-Toledo (MTD) initiated with a Market Perform at Wells Fargo.
News For T;AHP;HLT;OMED;SNAK;VSTM;TMO;MTD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 22, 2015
06:01 EDTTGoogle could launch wireless service today, WSJ reports
Subscribe for More Information
06:01 EDTTMOThermo Fisher reports Q1 adjusted EPS $1.63, consensus $1.61
Reports Q1 revenue $3.92B, consensus $4.0B
April 21, 2015
15:28 EDTTMONotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Coca-Cola (KO), consensus 42c... Boeing (BA), consensus $1.81... McDonald's (MCD), consensus $1.06... EMC (EMC), consensus 36c... Abbott Laboratories (ABT), consensus 42c... Thermo Fisher Scientific (TMO), consensus $1.61... Bank of New York Mellon (BK), consensus 59c... TE Connectivity (TEL), consensus $1.01... T. Rowe Price Group (TROW), consensus $1.14... St. Jude Medical (STJ), consensus 91c... Amphenol (APH), consensus 56c... Nielsen (NLSN), consensus 47c... Citizens Financial Group (CFG), consensus 34c... Autoliv (ALV), consensus $1.31... D.R. Horton (DHI), consensus 38c... Westinghouse Air Brake Technologies (WAB), consensus 95c... Huntington Bancshares (HBAN), consensus 19c... SEI Investments (SEIC), consensus 49c... AutoNation (AN), consensus 89c... Gentex (GNTX), consensus 25c... Ryder System (R), consensus $1.00... Owens Corning (OC), consensus 13c... NuStar Energy (NS), consensus 58c... Six Flags (SIX), consensus (67c)... Tupperware Brands (TUP), consensus 98c... MarketAxess Holdings (MKTX), consensus 64c... Lithia Motors (LAD), consensus $1.22... Knight Transportation (KNX), consensus 31c... Evercore Partners (EVR), consensus 58c... Potlatch (PCH), consensus 19c... Natus Medical (BABY), consensus 29c... AZZ (AZZ), consensus 59c... United Community Banks (UCBI), consensus 29c... Sonus Networks (SONS), consensus (31c)... Angie's List (ANGI), consensus 0c... Pacific Premier Bancorp (PPBI), consensus 27c.
14:38 EDTVSTMVerastem management to meet with Jefferies
Subscribe for More Information
13:40 EDTTEarnings Watch: AT&T sees Q1 charge of approximately $130M
Subscribe for More Information
13:06 EDTOMEDOncoMed presents data on stem cell programs at AACR
OncoMed Pharmaceuticals announced data from seven poster presentations at the American Association of Cancer Research Annual Meeting."We are pleased to have presented seven posters highlighting our ongoing discovery and development capabilities," said Paul J. Hastings, Chairman and CEO of OncoMed. "Leveraging our proprietary human tumor bank, human xenograft models and murine models, we have tested new combinations of our antibodies with standard-of-care chemotherapy and immunotherapy, as well as maximized optimal dosing regimens for these therapies. Our biomarker programs focus on patient selection for our clinical trials, and OncoMed continues to pursue breakthrough anti-cancer stem cell and immuno-oncology discoveries with multiple new targets and pathways."
09:06 EDTHLTHilton price target raised to $33 from $30 at Baird
Baird raised its price target on Hilton (HLT) to $33 from $30 ahead of its Q1 earnings report. The firm cited in-line peer valuation despite better growth expectations, additional asset monetization initiatives, and the potential for Blackstone (BX) to sell its shares, which would remove an overhang and boost liquidity. Baird reiterated its Outperform rating on Hilton.
08:09 EDTHLTHilton signs franchise license agreement to operate Hilton Graden Inn in Hawaii
Subscribe for More Information
07:57 EDTTAT&T April weekly volatility elevated into Q1 and outlook
Subscribe for More Information
07:36 EDTTU.S. mobile cariers could be pressured from new data plans, WSJ says
Subscribe for More Information
April 16, 2015
06:35 EDTOMEDOncoMed's Demcizumab shows positive Phase 1b clinical trial results
OncoMed presented new data from the Phase 1b clinical trial of demcizumab in patients with first-line advanced non-small cell lung cancer at the European Lung Cancer Conference. Demcizumab is a first-in-class monoclonal antibody targeting DLL4 with anti-cancer stem cell, dysangiogenesis and potential immune modulatory properties. Of 40 patients evaluable for efficacy, the overall RECIST response rate was 50% and an additional 15 patients had a best response of stable disease, yielding a clinical benefit rate of 88%. Median progression-free survival was 5.3 months and 5.8 months for the continuous and truncated cohorts, respectively. Prolonged PFS and OS were observed for a subset of patients treated with continuous demcizumab. A randomized Phase 2 trial of demcizumab with carboplatin and pemetrexed in first-line non-squamous NSCLC has been initiated and is enrolling subjects in Europe, Australia, and the United States.
April 15, 2015
07:41 EDTTMOEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
06:46 EDTTAT&T files lawsuit to challenge net neutrality order, WSJ says
AT&T filed a lawsuit to overturn the FCC's net neutrality order to reclassify the internet as a telecommunications service, reports the Wall Street Journal. The move is surprising, as AT&T didn't join in prior suits, the Journal adds. Reference Link
05:59 EDTHLTHilton REIT spinoff could add $3.50/share in value, says UBS
UBS analysts Robin Farley and Arpine Kocharyan say a tax-free spinoff of Hilton's owned hotel properties, which represent 31%-32% of the hotel chain's EBITDA, could create $3.00-$3.50 per share in value. The analysts explain in a note to investors this morning that while an owned portfolio offers the greatest upside in an upcycle, investors may prefer exposure to the more defensive and stable earnings stream created by a spinoff. They raised their price target for shares of Hilton to $35 from $33 and keep a Buy rating on the name. The stock closed yesterday down 21c to $30.27.
April 14, 2015
12:40 EDTTPCTEL lowers FY15 revenue to $124M-$130M from $133M-$138M, two estimates $130M
Following its March 5 acquisition of Nexgen Wireless, PCTEL (PCTI) reported in a regulatory filing earlier that on April 7, Samsung Electronics America, a Samsung (SSNLF) subsidiary, provided Nexgen and PCTEL with a notice of Samsung’s election to terminate, effective April 30, the contractor services agreement between Samsung and Nexgen. Nexgen furnishes services to Samsung under the CSA including Meridian software-based services and contract personnel. The termination applies to the CSA only and will have no effect on other agreements between Samsung and Nexgen or PCTEL. The company continues to forecast 15%-18% revenue growth over FY14 and views the Nexgen acquisition as accretive to earnings in FY15. The company has revised its overall revenue forecast for FY15 in light of reduced business with Samsung, the reduction in capital spending by AT&T (T), and a decline in new network infrastructure investment in the oil and gas market. The company has revised revenue guidance from $133M-$138M to $124M-$130M. Finally, the company and Nexgen have signed a term sheet calling for a material reduction of the total consideration paid or payable by PCTEL for the Nexgen assets, and a material reduction of the equity compensation for which John Thakkar, the founder and president of Nexgen, will be eligible. These reductions seek to align the asset acquisition costs with the revised revenue and EBITDA estimates.
10:16 EDTTMOHigh option volume stocks
High option volume stocks: NSAM ALU CJES BIG CMRX ERIC NTAP TMO KN CIG
April 13, 2015
20:16 EDTTUSTelecom files net neutrality lawsuit against FCC
Subscribe for More Information
10:00 EDTHLTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:12 EDTHLTHilton downgraded at Evercore ISI
Subscribe for More Information
06:59 EDTHLTHilton downgraded to Hold from Buy at Evercore ISI
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use